MEP55708A - Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide - Google Patents

Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide

Info

Publication number
MEP55708A
MEP55708A MEP-557/08A MEP55708A MEP55708A ME P55708 A MEP55708 A ME P55708A ME P55708 A MEP55708 A ME P55708A ME P55708 A MEP55708 A ME P55708A
Authority
ME
Montenegro
Prior art keywords
methoxy
benzamide
chloro
ethyl
sodium salt
Prior art date
Application number
MEP-557/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Heinrich Christian Englert
Uwe Gerlach
Tobias Metzenthin
Harald Schneider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP55708A publication Critical patent/MEP55708A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-557/08A 1999-04-16 2000-04-04 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide MEP55708A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids
PCT/EP2000/002984 WO2000063167A1 (en) 1999-04-16 2000-04-04 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide

Publications (1)

Publication Number Publication Date
MEP55708A true MEP55708A (en) 2011-05-10

Family

ID=7904803

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-557/08A MEP55708A (en) 1999-04-16 2000-04-04 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide

Country Status (33)

Country Link
US (1) US6723751B1 (he)
EP (2) EP1637519B1 (he)
JP (1) JP4662640B2 (he)
KR (1) KR100700302B1 (he)
CN (1) CN1168712C (he)
AR (1) AR023479A1 (he)
AT (2) ATE311364T1 (he)
AU (1) AU773246B2 (he)
BR (1) BR0010658A (he)
CA (1) CA2370388C (he)
CZ (1) CZ302459B6 (he)
DE (3) DE19917233A1 (he)
DK (1) DK1173418T3 (he)
EE (1) EE04612B1 (he)
ES (1) ES2251996T3 (he)
HK (1) HK1046270B (he)
HR (1) HRP20010744B1 (he)
HU (1) HU229082B1 (he)
IL (2) IL145921A0 (he)
ME (1) MEP55708A (he)
MX (1) MXPA01010275A (he)
MY (1) MY122588A (he)
NO (1) NO327798B1 (he)
NZ (1) NZ514788A (he)
PL (1) PL203809B1 (he)
RS (1) RS50916B (he)
RU (1) RU2235089C2 (he)
SI (1) SI1173418T1 (he)
SK (1) SK287175B6 (he)
TR (2) TR200501142T2 (he)
TW (1) TWI276622B (he)
WO (1) WO2000063167A1 (he)
ZA (1) ZA200108400B (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0612724T3 (da) * 1993-02-23 1997-06-16 Hoechst Ag Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til deres fremstilling og deres anvendelse som farmaceutika
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1195524C (zh) * 1998-09-10 2005-04-06 阿文蒂斯药物德国有限公司 苯磺酰(硫)脲与β－受体阻滞剂联合在制备用于心脏迷走神经机能障碍治疗和预防的药物中的用途

Also Published As

Publication number Publication date
ATE414059T1 (de) 2008-11-15
EP1637519B1 (en) 2008-11-12
BR0010658A (pt) 2002-02-19
KR100700302B1 (ko) 2007-03-29
NO20015014D0 (no) 2001-10-15
HRP20010744A2 (en) 2003-04-30
CZ20013672A3 (cs) 2002-01-16
NZ514788A (en) 2003-03-28
SK287175B6 (sk) 2010-02-08
CZ302459B6 (cs) 2011-06-01
JP4662640B2 (ja) 2011-03-30
JP2002542230A (ja) 2002-12-10
ZA200108400B (en) 2003-04-30
CA2370388C (en) 2009-10-13
MXPA01010275A (es) 2003-07-21
IL145921A (he) 2006-07-05
SI1173418T1 (sl) 2006-02-28
CA2370388A1 (en) 2000-10-26
WO2000063167A1 (en) 2000-10-26
DE19917233A1 (de) 2000-10-19
CN1354744A (zh) 2002-06-19
DK1173418T3 (da) 2006-04-10
EP1637519A1 (en) 2006-03-22
HUP0200791A3 (en) 2005-04-28
HU229082B1 (hu) 2013-07-29
NO327798B1 (no) 2009-09-28
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
HK1046270A1 (en) 2003-01-03
AU4542800A (en) 2000-11-02
TR200501142T2 (tr) 2005-08-22
ATE311364T1 (de) 2005-12-15
YU72001A (sh) 2004-07-15
EE200100532A (et) 2002-12-16
DE60040811D1 (de) 2008-12-24
EP1173418B1 (en) 2005-11-30
RS50916B (sr) 2010-08-31
ES2251996T3 (es) 2006-05-16
EP1173418A1 (en) 2002-01-23
EE04612B1 (et) 2006-04-17
SK14582001A3 (sk) 2002-01-07
IL145921A0 (en) 2002-07-25
DE60024431T2 (de) 2006-07-27
TWI276622B (en) 2007-03-21
NO20015014L (no) 2001-10-15
DE60024431D1 (en) 2006-01-05
AU773246B2 (en) 2004-05-20
PL351245A1 (en) 2003-04-07
CN1168712C (zh) 2004-09-29
MY122588A (en) 2006-04-29
TR200102993T2 (tr) 2002-03-21
US6723751B1 (en) 2004-04-20
HUP0200791A2 (hu) 2002-07-29
AR023479A1 (es) 2002-09-04
HK1046270B (zh) 2005-03-11
PL203809B1 (pl) 2009-11-30
HRP20010744B1 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
YU66101A (sh) Nova jedinjenja i kompozicije kao inhibitori proteaze
NO974335D0 (no) Laktam-holdige hydroksaminsyrederivater, deres fremstilling og deres anvendelse som inhibitorer for matriksmetallprotease
ME00558A (en) Pyrazole derivatives for treating hiv
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
BR0009411A (pt) Composto de anilina substituìda, e, processo para a preparação e uso de compostos
BR0311535A (pt) Uso de cianopirrolidinas substituìdas e preparações de combinações contendo as mesmas para o tratamento da hiperlipidemia e doenças associadas
EA199900217A1 (ru) Стабильная негигроскопичная кристаллическая форма n-[n-n-(4-(пиперидин-4-ил)бутаноил)-n-этилглицилового] соединения
ES2184304T3 (es) Procedimiento de preparacion de un perhidro-isoindol sustituido.
NO20025015D0 (no) Et pyridin-1-oksidderivat, og fremgangsmåte for dets overföring til farmasöytisk effektive forbindelser
YU15692A (sh) Hidrazonska jedinjenja, postupci za njihovo dobijanje, intermedijeri primenljivi za njihovo dobijanje i testicidni preparati koji ih sadrže
BR9609847A (pt) Derivados de N-(4-Benzila-substituída)-2-aminolactam
ATE253359T1 (de) Antithrombotische mittel
MEP55708A (en) Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide
DK0625153T3 (da) Nyt isoindolinonderivat, dets fremstilling og farmaceutiske præparater med et indhold deraf
DE69828522D1 (de) Antithrombotische mittel
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
AR004680A1 (es) Derivados de la alquenil-benzoilguanidina, procedimiento para prepararlos y preparaciones farmaceuticas que los contienen.
MXPA03001985A (es) Cristales novedosos de n-hidroxi-2 (s) -metil-5 -etoximetoxi-4 (s)-[n -(4-fenoxifenilcarbonil) amino] pentamida, proceso para su produccion y composiciones farmaceuticas que los contienen.
ES8506710A1 (es) Procedimiento para la obtencion de teofilin-7-acetato de ambroxol
KR910009654A (ko) 아미노피리딘, 아닐린 및 피콜릴아민의 피콜릴셀레노벤즈아미드
HUP0302860A2 (hu) Nátrium-hidrogén cserélő 1-típusú inhibitor hatású vegyület új etanolátjai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények